Myriad Genetics (MYGN) Tops Q4 EPS by 3c, provides guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall St set for higher open as Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mail
Get Alerts MYGN Hot Sheet
Price: $6.04 --0%
Revenue Growth %: -7.0%
Financial Fact:
Operating income: 6.2M
Today's EPS Names:
ATS, SICP, FTCO, More
Revenue Growth %: -7.0%
Financial Fact:
Operating income: 6.2M
Today's EPS Names:
ATS, SICP, FTCO, More
Join SI Premium – FREE
Myriad Genetics (NASDAQ: MYGN) reported Q4 EPS of $0.04, $0.03 better than the analyst estimate of $0.01. Revenue for the quarter came in at $196.6 million versus the consensus estimate of $194.8 million.
GUIDANCE:
Myriad Genetics sees FY2024 EPS of $0.00-$0.05, versus the consensus of ($0.02). Myriad Genetics sees FY2024 revenue of $820-840 million, versus the consensus of $834 million.
For earnings history and earnings-related data on Myriad Genetics (MYGN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Uber Q3 profit, revenue beat estimates as gross bookings jump 20%
- Avnet (AVT) Tops Q1 EPS by 97c ; Offers Guidance
- U.S. private payrolls rise by 86,000 in October, ADP says
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
